- |||||||||| hyoscine butylbromide oral / Generic mfg., memantine / Generic mfg.
Journal: Role of pro-inflammatory cytokines in Alzheimer's disease and neuroprotective effects of pegylated self-assembled nanoscaffolds. (Pubmed Central) - Jan 4, 2023
A significant reduction in the concentration of IL1β, IL-10 and TNF-α were noticed in serum, cerebral tissue and hepatic tissue of animal group treated with marketed memantine tablet (Admenta), pure memantine drug (MEMp), memantine-poly (lactic-co-glycolic acid) self-assembled nanoscaffolds (MEM-PLGA) SANs, Polyethylene Glycol coated memantine-poly (lactic-co-glycolic acid) self-assembled nanoscaffolds [(PEG-MEM-PLGA) SANs] and Polyethylene Glycol coated memantine-poly [(lactic-co-glycolic acid)] self-assembled nanoscaffolds grafted with Bone Marrow Derived Stem Cell ((PEG-MEM-PLGA) SANs-BMSc), whereas a high level of IL-6 was observed in hepatic tissue, cerebral tissue and renal tissues of normal and AD induced mice which showed the emerging potential of IL-6 cytokines that can trigger either neurons survival after injury or causing neurodegeneration and cell apoptosis. The Neuroregenerative potential of stem cells helps in the proliferation of neuronal cell and thus improves cognition in AD animal model.
- |||||||||| memantine / Generic mfg., rivastigmine / Generic mfg.
Journal: Anti-dementia drugs: a descriptive study of the prescription pattern in Italy. (Pubmed Central) - Jan 4, 2023
From a regulatory perspective, ADDs can be reimbursed by the National Health System only to patients diagnosed with AD; therefore, the off-label use of ADDs in patients with mild cognitive impairment may partially explain this phenomenon. The study extends knowledge on the use of ADDs, providing comparisons with studies from other countries that investigate the prescription pattern of ADDs.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Review, Journal: Role of multi-targeted bioactive natural molecules and their derivatives in the treatment of Alzheimer's disease: an insight into structure-activity relationship. (Pubmed Central) - Dec 30, 2022
This review summarises the structural properties required for bioactive natural molecules to show anti-Alzheimer's activity by emphasizing on SAR of several bioactive natural molecules targeting various AD pathologies, their key molecular interactions that are critical for target specificity, their role as multitargeted ligands, used with adjunctive therapy for AD followed by related US patents granted recently. This article highlights the significance of the structural features of natural bioactive molecules in the treatment of AD and establishes a connection between them.Communicated by Ramaswamy H. Sarma.
- |||||||||| Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
Enrollment open, Trial completion date, Trial primary completion date: Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge (clinicaltrials.gov) - Dec 30, 2022
P1, N=45, Recruiting,
This article highlights the significance of the structural features of natural bioactive molecules in the treatment of AD and establishes a connection between them.Communicated by Ramaswamy H. Sarma. Not yet recruiting --> Recruiting | Trial completion date: Jul 2026 --> Jul 2025 | Trial primary completion date: Jul 2026 --> Jul 2025
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen
Journal: The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease. (Pubmed Central) - Dec 29, 2022
As the standard of care progresses, clinicians should educate patients and their care providers on the implications of these advances and reinforce lifestyle changes that can delay or prevent the onset of disease in those at risk of AD. In doing so, care providers can deliver the best care possible.
- |||||||||| memantine / Generic mfg.
Review, Journal: The Efficacy of Vitamin D Supplementation in Patients With Alzheimer's Disease in Preventing Cognitive Decline: A Systematic Review. (Pubmed Central) - Dec 27, 2022
Another study evidenced significant improvement in Mini-Mental State Examination (MMSE) score when memantine and vitamin D were taken together compared to when memantine and vitamin D were taken independently. Studies have shown that vitamin D deficiency is associated with an increased risk of developing cognitive impairment. But there is no sufficient evidence indicating vitamin D supplementation can improve cognitive function in Alzheimer's disease.
- |||||||||| propranolol / Generic mfg.
Review, Journal: Propranolol for the management of behavioural and psychological symptoms of dementia. (Pubmed Central) - Dec 23, 2022
However, propranolol can be trialled among individuals with BPSD when symptoms have not responded adequately to other medications. Propranolol may also be used prior to embarking on trials of repetitive transcranial magnetic stimulation and electroconvulsive therapy among people with BPSD given the greater acceptance of this medication in the general population.
- |||||||||| memantine / Generic mfg.
ANALYSIS OF THE EFFECT OF MEMANTINE ON ANTI-PSYCHOTICS IN ALZHEIMER'S DISEASE USING THE COMMON DATA MODEL (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1436;
Results revealed good NPs stability once there was no significant variation in their physicochemical parameters and no signs of aggregation over 6 months. There were no significant differences in the prescribi ng of anti -psychotics between groups with N -methyl -d- aspartate receptor antagonist and acetylcholine esterase inhibitors using OMOP -CDM.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen
THE CURRENT AND FUTURE LANDSCAPE FOR PHARMACOTHERAPEUTICS IN ALZHEIMER'S DISEASE (On-Demand Oral Gallery G) - Dec 23, 2022 - Abstract #ADPD2023ADPD_255;
In this review we have discussed the approved drugs used in clinical practice for AD patients, as well as elucidated the priority areas and avenues for drug development to generate future trea tment options. As we approach a new era of precision medicine, we not only must consider the expansion in armamentarium of pharmacological treatment used, we can use biomarker confirmation to act as indications for specific therapies, to stratify for use i n the relevant patient subset, targeting an individual's unique neuropathology.
- |||||||||| memantine / Generic mfg.
Enrollment change: Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia (clinicaltrials.gov) - Dec 21, 2022
P4, N=42, Completed,
As we approach a new era of precision medicine, we not only must consider the expansion in armamentarium of pharmacological treatment used, we can use biomarker confirmation to act as indications for specific therapies, to stratify for use i n the relevant patient subset, targeting an individual's unique neuropathology. N=72 --> 42
- |||||||||| memantine / Generic mfg.
Review, Journal: GRIN2A-related epilepsy and speech disorders: A comprehensive overview with a focus on the role of precision therapeutics. (Pubmed Central) - Dec 16, 2022
The GRIN2A pathogenic variants cause gain or loss of function of NMDAR; the former can be treated with uncompetitive NMDAR antagonists, such as memantine, while the latter with NMDAR co-agonist serine...Precision treatments for GRIN2A-related disorders will benefit those who suffer from the condition and pave the way for new therapeutic approaches to a variety of other NMDAR-linked neurodegenerative and psychiatric diseases (schizophrenia, Parkinson's disease, Alzheimer's disease, and so on). Furthermore, more research into GRIN2A-related disorders will help us better understand the neuroinflammatory and neuroimmunological basis of epilepsy, as well as the pathological and physiological network activation mechanisms that cause sleep activation of central-temporal spikes and language impairment.
- |||||||||| Review, Journal: New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. (Pubmed Central) - Dec 16, 2022
Among them, five drugs, including methylcobalamin, masitinib, AMX0035, CNM-Au8, and tofersen, have shown potent therapeutic effects in clinical trials. Recently, AMX0035 has been the third medicine approved by the FDA for the treatment of ALS after riluzole and edaravone.
- |||||||||| sodium phenylbutyrate / Generic mfg.
Cerebrospinal Fluid Biomarker Effects From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the PEGASUS Trial (Grand Ballroom AB - Tower 2) - Dec 9, 2022 - Abstract #CTAD2022CTAD_343;
P2
Results from PEGASUS provide the first-in-human evidence for a treatment effect of PB and TURSO on AD pathology and pathways of inflammation, synaptic function, oxidative stress, and neurodegeneration, complementing preclinical studies that showed a biologic effect for PB and TURSO both individually and in combination in AD All abstracts are embargoed until the day and time of presentation at the CTAD Conference S48 models. Taken together, these findings may be used to inform the design of subsequent trials and provide support for further clinical development of PB and TURSO for AD and other neurodegenerative diseases.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen
Review, Journal: Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab. (Pubmed Central) - Dec 8, 2022
Furthermore, memantine, an NMDA receptor antagonist, is authorized for moderate-to-severe dementia...Unfortunately, at this time, aducanumab's risks outweigh the benefits with a questionable approval process by the Food and Drug Administration (FDA). However, given the potential disease-modifying capabilities of aducanumab, other disease-modifying options may become available by possibly reducing inflammation, preventing Aβ plaques from clumping, or keeping tau proteins from tangling.
- |||||||||| Cognex (tacrine) / Shionogi
Journal: Recent developments in tacrine-based hybrids as a therapeutic option for Alzheimer's disease. (Pubmed Central) - Dec 6, 2022
Here, tacrine-based derivatives including heterocyclic structures such as dihydroxypyridine, chromene, coumarin, pyrazole, triazole, tetrahydroquinolone, dipicolylamine, arylisoxazole were reported with promising anti-AD effects compared to tacrine. In vitro and in vivo assays showed that new tacrine-based hybrids, which are selective, neuroprotective, and non-hepatotoxic, might be considered as remarkable anti-AD drug candidates for further clinical studies.
- |||||||||| memantine / Generic mfg.
Phase classification: Therapy in Amyotrophic Lateral Sclerosis (TAME) (clinicaltrials.gov) - Nov 29, 2022
P2b, N=89, Completed,
The results from the gantenerumab phase 3 programs are expected by the end of 2022 and will add critical information to the collective knowledge on the search for effective AD treatments. Phase classification: P2 --> P2b
- |||||||||| memantine / Generic mfg.
Review, Journal: Multidisciplinary Management of Brain Metastasis from Breast Cancer. (Pubmed Central) - Nov 27, 2022
Stereotactic radiosurgery (SRS) is preferred over whole-brain radiotherapy (WBRT) in most patients presenting with a limited number of BMs, whereas WBRT with hippocampal-sparing and concomitant memantine is preferred for patients with multiple BMs. There is a growing role for systemic therapy, in some cases in lieu of local therapy, particularly in patients with HER2+ breast cancer.
- |||||||||| memantine / Generic mfg.
Journal: Capabilities of combined therapy of Alzheimer's disease (Pubmed Central) - Nov 23, 2022
Most studies have shown that a combination of both classes is better than monotherapy. The review discusses the pharmacological properties, efficacy and safety data of memantine and donepezil.
- |||||||||| memantine / Generic mfg.
Review, Journal: Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias. (Pubmed Central) - Nov 22, 2022
Eligible patients should be treated with the cognitive-enhancing medications, the cholinesterase inhibitors and memantine...There is hope that Alzheimer disease can be treated by using monoclonal antibodies that target amyloid beta, although more trials are needed. Holistic, patient-centered care can enhance quality and extend the time that the patient can live safely in the community.
- |||||||||| memantine / Generic mfg.
Review, Real-world evidence: Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease. (Pubmed Central) - Nov 22, 2022
Limitations in reporting led to unclear risk of bias. The results reveal a pattern of use of symptomatic treatment in eAD beyond approved labels and highlights the opportunity for new consensus guidelines to inform clinical practice.
- |||||||||| memantine / Generic mfg.
Journal: Moving beyond first-line treatment options for OCD. (Pubmed Central) - Nov 22, 2022
Several potential strategies have been evaluated for enhancing patient response, including high-dose SSRI therapy, antipsychotic augmentation, and memantine augmentation. Three patient cases are used to explore treatment guidelines, evaluate existing literature, and provide pharmacotherapy recommendations for the management of patients with OCD when first-line therapy fails.
- |||||||||| memantine / Generic mfg.
Journal: Design, Fabrication, optimization and characterization of Memantine loaded biodegradable PLGA nanoscaffolds for treatment of Alzheimer's disease. (Pubmed Central) - Nov 22, 2022
The analysis of model showed the significant individual effect of PLGA and significant interactive effect of Pluronics F-127 and rotation speed on drug loading and porosity. Further, its physicochemical characterazation, and in-vitro (drug release kinetics, and PAMPA study), Ex-vivo (enzyme inhibition assay and pro-inflammatory cytokines study) and in-vivo (neurobehavioral and histological study) studies were performed to evaluate the potential of memantine-loaded nanoscaffolds in the treatment of Alzheimer's disease (AD).
- |||||||||| memantine / Generic mfg.
Journal: Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study. (Pubmed Central) - Nov 19, 2022
The currently available pharmacological treatments for AD mainly contain cholinesterase inhibitors (AChE-I) and N-methyl-D-aspartic acid (NMDA) receptor antagonists (i.e., memantine)...These alterations were also found to be associated with global cognitive scores. Overall, our findings indicate that entropy measures could be useful to show medication effects in AD.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
Retrospective data, Review, Journal: The efficacy of pharmacological interventions to improve cognitive and behavior symptoms in people with dementia: A systematic review and meta-analysis. (Pubmed Central) - Nov 19, 2022
The study subjects who received donepezil 5 mg/day, donepezil 10 mg/day, and galantamine 24 mg/day had improved cognition symptoms (ADAS-cog) score of -1.46 (95% CI = -2.24, -0.68, z = 3.67, p < 0.001), -2.31 (95% CI = -3.30, -1.31, z = 5.45, p < 0.001) and -3.04 (95% CI = -4.16, -1.92, z = 5.31, p < 0.001) respectively. The current meta-analysis suggests significant benefits of cholinesterase inhibitors such as donepezil (5 and 10 mg/day) and galantamine on cognitive symptoms.
- |||||||||| memantine / Generic mfg.
PK/PD data, Journal: A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles. (Pubmed Central) - Nov 18, 2022
The gamma scintigraphy studies showed higher uptake of the drug in the target site through the intranasal route and pharmacodynamic studies indicated that nanoparticles were able to inhibit the spatial memory impairment significantly as compared to the control group. The findings clearly indicated that the developed memantine nanoparticles could act as an alternative approach for the management of Alzheimer's disease.
- |||||||||| memantine / Generic mfg.
Preclinical, Journal: Suppressed prefrontal neuronal firing variability and impaired social representation in IRSp53-mutant mice. (Pubmed Central) - Nov 18, 2022
Treatment of memantine, an NMDA receptor antagonist that rescues social deficit in IRSp53-mutant mice, alleviates the reduced burst firing of IRSp53-mutant pyramidal mPFC neurons. These results suggest that suppressed neuronal activity dynamics and burst firing may underlie impaired cortical encoding of social information and social behaviors in IRSp53-mutant mice.
- |||||||||| Sanvar (vapreotide) / PharmGKB, Debiopharm, Bausch Health, Eisai
Journal, IO biomarker: Neuroprotective Effects of Vapreotide on Tau Transfection-Induced Neurodegeneration. (Pubmed Central) - Nov 17, 2022
With the qRT-PCR method, it was found that Vapreotide, decreased the BAX/BCL2 (50 µM-p < 0.001; 100 µM-p < 0.01; 200 µM-p < 0.001) expression level and decreased the expression level (50 µM-p < 0.01; 100 µM-p < 0.01; 200 µM-p < 0.001) of the APOE4 gene, which constitutes a genetic risk for AD. This study demonstrates a potential therapeutic role for a somatostatin analogue Vapreotide in Alzheimer's disease.
|
